Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

Diamond Equity Research – Advancing Pipeline with Strategic Clinical Developments

Monday, March 18, 2024 1 min read
Key Takeaway: Radiopharm Theranostics is advancing its clinical pipeline with the initiation of a Phase 1/2a study for BetaBart (RV-01). The company has also received IND approval from the US FDA to target B7H3 with this therapeutic. Additionally, positive updates have been reported across four of its programs, indicating progress in its clinical developments.

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm Theranostics has initiated a Phase 1/2a clinical study.
  • The company received IND approval from the US FDA for Betabart (RV-01).
  • Positive clinical updates have been provided across four programs.

Full Press Release Details

• Updates
• PDF
• March 18, 2024
Loading Viewer…

More Announcements & Updates

• Analyst Reports
• May 14, 2026
• Announcements
• March 4, 2022
• Announcements
• November 16, 2023
• Announcements
• October 17, 2022

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the Phase 1/2a study for BetaBart?

Radiopharm Theranostics has initiated a Phase 1/2a clinical study for BetaBart (RV-01).

What recent FDA approval did Radiopharm receive?

Radiopharm received IND approval from the US FDA to initiate a therapeutic study targeting B7H3.

How many programs received positive updates?

Radiopharm provided positive clinical updates across four of its programs.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics BetaBart Phase 1/2a FDA IND approval clinical study
Last updated: Mar 18, 2024